Citadel Advisors
HRMY icon

Citadel Advisors’s Harmony Biosciences HRMY Stock Holding History

Citadel Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$757K Sell
20,800
-15,100
-42% -$476K ﹤0.01% 8880
2026
Q1 		$1.01M Buy
35,900
+8,500
+31% +$279K ﹤0.01% 7638
2025
Q4 		$1.03M Buy
27,400
+4,400
+19% +$145K ﹤0.01% 7339
2025
Q3 		$634K Buy
23,000
+16,200
+238% +$558K ﹤0.01% 8558
2025
Q2 		$215K Sell
6,800
-4,000
-37% -$129K ﹤0.01% 10520
2025
Q1 		$358K Sell
10,800
-10,100
-48% -$362K ﹤0.01% 9192
2024
Q4 		$719K Buy
20,900
+3,100
+17% +$107K ﹤0.01% 7757
2024
Q3 		$712K Buy
17,800
+1,100
+7% +$38.6K ﹤0.01% 7514
2024
Q2 		$504K Sell
16,700
-1,000
-6% -$30.1K ﹤0.01% 8029
2024
Q1 		$594K Sell
17,700
-1,100
-6% -$35.3K ﹤0.01% 7995
2023
Q4 		$607K Sell
18,800
-23,500
-56% -$656K ﹤0.01% 7674
2023
Q3 		$1.39M Buy
42,300
+6,100
+17% +$212K ﹤0.01% 5926
2023
Q2 		$1.27M Buy
36,200
+15,700
+77% +$542K ﹤0.01% 5961
2023
Q1 		$669K Buy
20,500
+15,600
+318% +$710K ﹤0.01% 7681
2022
Q4 		$270K Buy
+4,900
New +$269K ﹤0.01% 9543

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's HRMY Position: Q2 2026 in Review

Citadel Advisors reduced its Harmony Biosciences (HRMY) stake by 56% in Q2 2026, selling an estimated $10.4M and leaving 255,810 shares worth $9.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

Citadel Advisors first reported a position in HRMY in Q3 2020 and has held it in 23 quarters since. The position peaked at $47.1M in Q4 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Citadel Advisors held 255,810 shares of Harmony Biosciences worth $9.31M as of Q2 2026.
  • Citadel Advisors sold 329,813 Harmony Biosciences shares in Q2 2026, an estimated $10.4M.
  • Harmony Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3677 holding.
  • Citadel Advisors first reported a position in Harmony Biosciences in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Harmony Biosciences position peaked at $47.1M in Q4 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.